1. Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018.
- Author
-
Schmedes, Sarah E., Patel, Dhruviben, Dhal, Simran, Kelley, Julia, Svigel, Samaly S., Dimbu, Pedro Rafael, Adeothy, Adicatou-Laï, Kahunu, Gauthier Mesia, Nkoli, Papy Mandoko, Beavogui, Abdoul Habib, Kariuki, Simon, Mathanga, Don P., Koita, Ousmane, Ishengoma, Deus, Mohamad, Ally, Hawela, Moonga, Moriarty, Leah F., Samuels, Aaron M., Gutman, Julie, and Plucinski, Mateusz M.
- Subjects
PLASMODIUM falciparum ,TREATMENT failure ,TREATMENT effectiveness ,DRUG resistance ,DRUG utilization ,DRUG therapy for malaria ,PROTEINS ,PROTOZOA ,RESEARCH ,GENETIC mutation ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,ANTIMALARIALS - Abstract
The spread of drug resistance to antimalarial treatments poses a serious public health risk globally. To combat this risk, molecular surveillance of drug resistance is imperative. We report the prevalence of mutations in the Plasmodium falciparum kelch 13 propeller domain associated with partial artemisinin resistance, which we determined by using Sanger sequencing samples from patients enrolled in therapeutic efficacy studies from 9 sub-Saharan countries during 2014-2018. Of the 2,865 samples successfully sequenced before treatment (day of enrollment) and on the day of treatment failure, 29 (1.0%) samples contained 11 unique nonsynonymous mutations and 83 (2.9%) samples contained 27 unique synonymous mutations. Two samples from Kenya contained the S522C mutation, which has been associated with delayed parasite clearance; however, no samples contained validated or candidate artemisinin-resistance mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF